Comparative Pharmacology
Head-to-head clinical analysis: A POXIDE versus FLURAZEPAM HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A POXIDE versus FLURAZEPAM HYDROCHLORIDE.
A-POXIDE vs FLURAZEPAM HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABA-A receptor positive allosteric modulator; increases chloride ion influx and neuronal hyperpolarization.
Positive allosteric modulator of GABA-A receptors, enhancing the inhibitory effects of GABA by increasing the frequency of chloride channel opening.
GERD: 20 mg orally once daily for 4-8 weeks. Erosive esophagitis: 40 mg once daily for 8 weeks. H. pylori eradication: 20 mg twice daily with amoxicillin and clarithromycin for 14 days.
15-30 mg orally at bedtime as a single dose for insomnia; maximum dose 30 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-18 hours (mean 15 hours) in adults with normal renal function. Prolonged to 24-36 hours in elderly or moderate renal impairment (CrCl < 50 mL/min).
Terminal elimination half-life: 40-114 hours (mean 74 hours); accumulates extensively with repeated dosing, leading to prolonged sedation.
Renal excretion accounts for 60-70% of elimination, predominantly as unchanged drug. Biliary/fecal excretion accounts for 20-30%, with approximately 10% eliminated in feces as metabolites.
Renal: 90% (as metabolites, <1% unchanged); Fecal: <10%; Biliary excretion minimal.
Category C
Category D/X
Benzodiazepine
Benzodiazepine